Snapshot: August Highlights
Executive Summary
A selection of articles you might have missed from August 2022, including a discussion on fake medicines and what's needed to tackle their existence, the die down of SPAC deals and how device-activated drugs may unlock new therapeutic avenues.
You may also be interested in...
Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust
2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public.
Deals Shaping The Industry, February 2024
An interactive look at pharma, medtech, and diagnostics deals made during February 2023. Data courtesy of Biomedtracker.
Execs On The Move: February 2024
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.